Novo Nordisk CEO says the obesity drug race is shifting from efficacy to quality
Novo is putting oral treatments and more personalized options first as the market moves past raw weight loss numbers, the CEO told Chosun Ilbo.
Recap by typeshit. Full story at 조선일보.